Analysis Of Estimated Clinical Benefit Of Newly Approved Drugs For US Patients With Acute Myeloid Leukemia

Leukemia Research
31 Jul, 2020 ,

Audrey A.Tran et.al. conducted a study to assess  the demographic and subgroup characteristics of patients with newly diagnosed cases of acute myeloid leukemia, FDA data on drugs indicated for Acute Myeloid Leukemia approved from 1969 through November 2019, 3) measures of response from drug labels, and published reports documenting the response for drugs approved before the 1979 Labeling Act. The researchers concluded that it is true that the number of available therapies approved by the FDA has increased dramatically, it is not yet clear how large of a clinical benefit we can expect to see from these new lines of therapies.

Source